Found 57 clinical trials
Molecular Mechanisms of Antipsychotic-induced Insulin Resistance
This study will investigate the molecular mechanisms of atypical-antipsychotic induced insulin resistance. This will be accomplished by administering olanzapine or placebo to healthy subjects for 7 days and analyzing genetic and protein changes in peripheral tissues known to play an important role in insulin resistance pathophysiology.
- 17 views
- 24 Feb, 2022
- 1 location
Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
Plasma half-life has routinely been used to establish the dosing schedule of antipsychotics; for example, it is recommended that agents with a short plasma half-life be administered multiple
- 141 views
- 23 Feb, 2022
- 1 location
Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia
Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Vildagliptin can improve lipid levels in obese patients. The investigators conducted a randomized
- 0 views
- 21 Mar, 2022
- 1 location
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
Purpose: Tardive dyskinesia (TD) is a involuntary movement disorder that can occur following long term treatment with antipsychotic medications and for which few treatment options exist. This study will test the efficacy of pyridoxine (also known as vitamin B6) for TD. This will be an 8 week double-blind, placebo-controlled, randomized …
- 320 views
- 01 May, 2022
- 1 location
Monotherapy of an NMDA Enhancer for Schizophrenia
deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or
- 0 views
- 16 Feb, 2021
- 1 location
iTBS on Negative Symptoms and Cognitive Function in Schizophrenia
The negative symptoms and cognitive deficits are common in patients with schizophrenia, and do not respond well to antipsychotics. The effective treatments for negative symptoms and cognitive
- 0 views
- 10 May, 2022
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
experimental medicine approach. Antipsychotics are the major therapeutic tool for chronic psychotic disorders, including schizophrenia, but do not significantly alter their course or real-life impact. Specific
- 0 views
- 25 Mar, 2022
- 1 location
Add-on MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis
Antipsychotics affects the brain's dopamine system, and the drugs reduce delusions, hallucinations, and disorganized thinking, which are cardinal symptoms of psychotic disorders. However
- 0 views
- 05 Sep, 2021
- 1 location
Propranolol for Challenging Behaviors in Autism
can be effective in individuals with ASD who display severe aggression and have not responded to antipsychotics or mood stabilizers. Concerns regarding the safety of high dose propranolol have limited
- 27 views
- 14 Feb, 2022
- 1 location
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis (DROP)
In psychotic disorders, negative symptoms and cognitive impairment are difficult to treat with antipsychotics, which are mostly effective for positive symptoms. However, it is important that
- 0 views
- 21 Mar, 2022
- 1 location